바로가기
메인메뉴로 바로가기
콘텐츠 바로가기
하단메뉴로 바로가기
패밀리사이트 바로가기


진료과

  • 연세암병원-종양내과, 위암센터

전문진료분야

  • <종양내과> 위암, 유방암, 항암약물치료, 신약치료, 암유전자기반 맞춤치료

진료시간표

인터넷진료예약
의사시간표
진료시간
오전 암병원 암병원 암병원
오후

교육 및 임상 경력

  • 1989-1991  연세암센터  혈액종양내과  강사
  • 1992-1993  Visiting  Researcher,  Lombardi  Cancer  Center  Georgetown  University  School  of  Medicine  Washington  D.C.,  U.S.A.
  • 1994-1998  연세의료원  암센터  혈액종양내과  조교수
  • 1999-2003  연세의료원  암센터  혈액종양내과  부교수
  • 2005-2007  연세의료원  암센터  종양학과  과장
  • 2008-2009  연세의료원  암센터  종양내과장
  • 2009-2013  연세의료원  암센터  원장
  • 2004-현  재  연세의료원  연세암병원  종양내과  교수
  • 2005-현  재  국가  바이오칩  연구개발센터  소장
  • 2013-현  재  연세의료원  송당암연구센터소장

학술관련경력

  • 대한내과학회 회원
  • 대한암학회 회원, 학술이사
  • 대한 암재단 이사
  • 대한항암요법연구회 회장
  • 미국 임상암학회 회원
  • 미국 암연구학회 회원
  • 유럽 암학회 회원
  • 대한 암학회 감사
  • 재단법인 한국암학술재단 이사

주요 관심분야

  • 유방암, 위암
  • 암전이 억제와 신생혈관 생성 억제 연구
  • 유전체/바이오칩 연구
  • 신약개발 및 임상시험

학력사항

  • 1982 연세대학교 의과대학 학사
  • 1884 연세대학교 의과대학 석사
  • 1992 연세대학교 의과대학 박사

논문

  • 1. Experience with a controlled-release oral morphine for cancer pain management. BS Kim, HC Chung: Postgrad Med J 67:S82, 1991
  • 2. Overexpression of erbB-2 protein in gastric adenocarcinoma ―A Potential Role in Therapeutic Response to Adjuvant 5-FU-Doxorubicin Regimen Jae Kyung Roh, Soon Myung Paik, Hyun Cheol Chung, Woo Ik Yang, Ho Kuen Kim, In Joon Choi, Eun Hee Koh, Kyung Sik Lee, Jin Sik Min, Jeong Ku Yoon, Byung Soo Kim: Jpn J of Cancer and Chemother 19:1207-1219, 1992
  • 3. Phase II trial for combined external radiotherapy and hyperthermia for unresectrable hepatoma. Byung Soo Kim, Hyun Cheol Chung, Jin Sil Seong, Chang Ok Suh, Gwi Eon Kim Cancer Chemotherapy Pharmacology 31 s119-127, 1992
  • 4. Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, W Choi, HY Lim, EH Koh, JK Roh, SK Kim, WY Lee, BS Kim. Lung Cancer 10:287-296, 1994
  • 5. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. F Czubayko, RV Smith, HC Chung, A Wellstein. J Biol Chem 154-159, 1994
  • 6. Perioperative blood transfusions and prognosis in patients with curatively resected locvally advanced gastric cancer. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, JK Roh, JS Min, KS Lee, BS Kim, HY Lim. Oncology 52:170-175, 1995
  • 7. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Kyong Sik Lee, Sun Young Rha, Sea Joong Kim, Joo Hang Kim, Jae Kyung Roh, Byung Soo Kim, Hyun Cheol Chung. Clin Exp Metastasis 14:512-519, 1996
  • 8. Overexpression of c-erbB-2 protein in gastric cancer by immunohistochemical stain. Hye Ran Lee, Hyo Dong Uhm, Joong Bae Ahn, Sun Young Rha, Jae Yong Cho, Jong In Lee, Kyong Hee Lee, Hyun Cheol Chung, Jae Kyong Roh, Jin Sik Min, Kyong Sik Lee, Dong Hwan Shin, Byung Soo Kim, Soon Won Hong, Jin Hyuk Choi. Oncology 53:192-197, 1996
  • 9. Gastric cancer in young patients who underwent curative resection. Comparative studies with older patients. JH Choi, HC Chung, NC Yoo, HR Lee, KH Lee, JK Roh, CS Park, JS Min, KS Lee, BS Kim, HY Lim. Am J Clin Oncol 19:45-48, 1996
  • 10. Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. JY Cho, YH Lee, KY Chung, SK Kim, SJ Gong, NC Yoo, HC Chung, JK Roh, BS Kim. Cancer 79:462-467, 1997
  • 11. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Joon Oh Park, Sun Young Rha, Jae Yong Cho, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Am J Clin Oncol. 20:569-572, 1997
  • 12. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. Park Joon Oh, Chung Hyun Cheol, Cho Jae Yong, Rha Sun Young, You Nae Choon, Noh Sung Hoon, Kim Chong Bae, Min Jin Sik, Kim Byung Soo. Am J Clin Oncol. 20:484-489, 1997
  • 13. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Sun Young Rha, Jae Kyung Roh, Kyong Sik Lee, Jin Sik Min, Byoung Soo Kim, Hyun Cheon Chung. Breast Cancer Res Treat 43:175-181, 1997
  • 14. P-glycoprotein: an intermediate and point of drug response to induction chemotherapy in locally advanced breast cancer. Hyun Cheol Chung, Sun Young Rha, Joo Hang Kim, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, Kyi Beom Lee. Breast Cancer Res Treat 42:65-72, 1997
  • 15. Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Sun Young Rha, Sung Hoon Noh, Hyun Joo Kwak, Anton Wellstein, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Cancer Letters. 118:37-46, 1997
  • 16. Relationship between p53 overexpression and gastric cancer progression. Hyo Dong Uhm, Soo Jung Gong, Dong Hwan Shin, Jin Hyuk Choi, Hye Ran Lee, Sung Hoon Noh, Byung Soo Kim, Jae Yong Cho, Sun Young Rha, Nae Choon Yoo, Hyun Cheol Chung, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim. Oncology 54: 166-170, 1997
  • 17. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Sun Young Rha, Woo Ick Yang, Jae Kyung Roh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, and Hyun Cheol Chung. Oncology Reports 5:875-879, 1998
  • 18. Telomerase activity and telomere length in various cell lines: Changes of telomerase activity can be another method for chemosensitivity evaluation. Kyu Hyun Park, Sun Young Rha, Chang Han Kim, Tae Soo Kim, Nae Choon Yoo, Jae Kyung Roh, Sung Hoon Noh, Jin Sik Min, Kyong Sik Lee, Byung Soo Kim, Hyun Cheol Chung. International J Oncology 13:489-495, 1998
  • 19. Alpha-fetoprotein-producing gastric cancer. Ruth Lee, Sun Young Rha, Joong Bae Ahn, Kwang Yong Shim, Jin Hyuk Choi, Ho Young Lim, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Jin Sik Min, Byung Soo Kim, Hyun Cheol Chung. Oncol Rep 5:1179-1184, 1998
  • 20. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Chung HC, Rha SY, Park JO, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Kim JJ. Breast Cancer Res Treat 49:41-50, 1998
  • 21. Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast. Chung HC, Rha SY, Ahn JB, Shim KW, Yoo NC, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ. Int J Mol Med 2:465-470, 1998
  • 22. Effects of Interleukin-2 transduction into the human hepatoma cell lines using retroviral vector. Gong SJ, Yoo NC, Lee H, Shin DH, Uhm HD, Jeong SJ, Cho JY, Rha SY, Kim YS, Chung HC, Roh JK, Min JS, Kim BS. Oncol Rep 6:49-54, 1999
  • 23. Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Sun Young Rha, Hyun Cheol Chung, Soo Jung Gong, Kwang Yong Shim, Joong bae Ahn, Woo Ick Yang, Kyu Ho Shin, Nae Choon Yoo, Joo Hang Kim, Jae Kyung Roh, Chong In Lee, Byung Soo Kim. Oncol Rep 6:631-637, 1999
  • 24. Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer. Rha SY, Noh SH, Kim TS, Yoo NC, Roh JK, Min JS, Kim BS, Kim MY, Chung HC. Int J Mol Med 4:203-212, 1999
  • 25. Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast. Rha SY, KH Pak, Kim TS, Yoo NC, Yang WI, Roh JK, Min JS, Lee KS, Kim BS, Choi JH, Lim HY, Chung HC. Int J Oncol 15:839-845, 1999
  • 26. Correlation of tissue and blood plasminogen activation system in breast cancer. Rha SY, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Chung HC. Cancer Letter 150:137-145, 2000
  • 27. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Gong SJ, Rha SY, Chung HC, Yoo NC, Roh JK, Yang WI, Lee KS, Min JS, Kim BS, Chung HC. Int J Mol Med 6:301-305, 2000
  • 28. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. HC Jeung, SY Rha, SH Noh, JS Min, BS Kim, HC Chung. Cancer 91:2016-2025, 2001
  • 29. Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Ahn JB, Shim KY, Jeung HC, Rha SY, Yoo NC, Kim NK, Roh JK, Min JS, Kim BS, Chung HC. Cancer Letters 167: 215-224, 2001 (
  • 30. Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials. NK Kim, JS Min, JK Park, SH Yun, JS Sung, HC Chung, JK Roh. Jpn J Clin Oncol 31:25-29, 2001
  • 31. Early postoperative interperitoneal chemotherapy with mictomycinC, 5-fluorouracil and cisplatin for advanced gastric cancer. Sung Hoon Noh, Chang Hak Yoo, Hyun Cheol Chung, jae Kyung Roh, Dong Woo Shin, Jin Sik Min. Oncology 60:24-30, 2001
  • 32. The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck. GE Kim, WI Yang, SW Lee, YB Kim, CO Suh, JH Yoon, TY Oh, HC Chung, BS Kim. Cancer 91:2343-2352, 2001
  • 33. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. HC Jeung, SY Rha, WI Jang, SH Noh, HC Chung. Br J Surg 89:460-466, 2002
  • 34. Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Rha SY, Jeung HC, Roh JK, Kim JJ, Noh SH, Min JS, Kim BS, Chung HC. Int J Mol Med. 10:251-256, 2002
  • 35. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Kim JH, Shim JS, Lee SK, Kim KW, Rha SY, Chung HC, Kwon HJ. Jpn J Cancer Res. 93:1378-1385, 2002.
  • 36. Expression of autotoxin (NPP-2) is closely linked to invasiveness of breast cancer cells. SY Yang, JS Lee, CG Park, SH Kim, SY Hong, HC Chung, SK Min, WH Jeung, HW Lee, HY Lee. Clin Exp Metastasis 19:603-608, 2002 (
  • 37 An integrated proteome database for two-dimentional electrophoresis data analysis and laboratory information management system. SY Cho, KS Park, JE Shim, MS Kwon, KH Joo, WS Lee, J Chang, H Kim, HC Chung, HO Kim, YK Paik. Proteomics 2:1104-1113, 2002
  • 38 Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho HS, Choi YH, Kim YH, Rha SY, Chung HC, An SW. Int J Oncol. 22:741-750, 2003
  • 39 Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer. Sohn JH, Jeung HC, Shin HJ, Rha SY, Roh JK, Noh SH, Min JS, Kim BS, Jang WI, Chung HC. Am J Clin Oncol. 26:203-209, 2003
  • 40. Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer. Schneider BG, Rha SY, Chung HC, Bravo JC, Mera R, Torres JC, Plaisance KT Jr, Schlegel R, McBride CM, Reveles XT, Leach RJ. J Clin Pathol 56:141-149, 2003
  • 41. Coordination modes vs antitumor activity: synthesis and antitumor activity of novel platinum (II) complexes of N-substituted amino dicarboxylic acids. YS Kim, R Song, HC Chung, MJ Jun, YS Sohn. J Inorg Biochem 98:98-104, 2004
  • 42. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. GE Kim, YB Kim, NH Cho, HC Chung, HR Pyo, JD Lee, TK Park, WS Koom, M Chun, CO Suh. Clin Cancer Res 10:1366-1374, 2004
  • 43. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. MY Seo, SY Rha, SH Yang, SC Kim, GY Lee, CH Park, WI Yang, JB Ahn, BW Park, HC Chung. Int J Mol Med 13:17-24, 2004
  • 44. Fabrication of high quality cDNA Microarray using a small amount of cDNA. CH Park. HJ Jeong, JJ Jung, GY Lee, SC Kim, TS Kim, SH Yang, HC Chung, SY Rha. Int J Mol Med 13:675-679, 2004
  • 45. Lack of correlation between P-glycoprotein and chemotherapy resistance in Nasal NK/T-cell lymphomas. GE Kim, WI Yang, SW Lee, SY Rha, HC Chung, JH Cho, CO Suh, NC Yoo, JK Roh, JS Hahn. Leuk Lymphoma 45:1857-1864, 2004
  • 46. Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. SY Hong, MH Lee, KS Kim, HC Chung, JK Roh, WJ Hyung, SH Noh, SH Choi. World J Gastroenterol 10:1191-1197, 2004
  • 47. Spearman’s footrule as a measure of cDNA microarray reproducibility. BS Kim, SY Rha, GB Cho, HC Chung. Genomics. 84:441-448, 2004
  • 48. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. SJ Gong, CJ Jin, SY Rha, HC Chung. Cancer Lett 214:215-224, 2004
  • 49. Statistical method of determining a cut off value between normal and disease group. Inyoung Kim, Yeon-ho Coi, Hyun Cheol Chung, Sun Young Rha, Byung Soo Kim. Bull Informatics and Cybernetics 36:63-72, 2004
  • 50. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. HY Lim, MW Ahn, HC Chung, TA Gardner, CH Kao, SJ Lee, SJ Kim. Cancer Gene Ther 11:532-538, 2004
  • 51. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS. Ann Oncol. 15:1344-1347, 2004
  • 52. Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction. M Yeo, SY Rha, HC Jeung, XH Shen, SH Yang, SW An, JK Roh, HC Chung. FEBS Letters 579:127-132, 2005
  • 53. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Marie Yeo, Sun Young Rha, Hei Cheul Jeung, Shen Xiong Hu, Sang Hwa Yang, Yang Seok Kim, Sung Whan An, Hyun Cheol Chung. Int J Cancer 114:484-489, 2005
  • 54. Statistical methods of translating Microarray data into clinically relevant diagnostic information in colorectal cancer. Kim BS, Kim I, Lee S, Kim S, Rha SY, Chung HC. Bioinformatics. 21: 517-528, 2005
  • 55. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray Tae Moon Kim, Ha Jin Jeong, Min Young Seo, Sang Chul Kim, Gabee Cho, Chan Hee Park, Tae Soo Kim, Kyu Hyun Park, Hyun Cheol Chung, and Sun Young Rha. Clin Cancer Res 11: 79-86, 2005
  • 56. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients Sang Hwa Yang, Min Young Seo, Ha Jin Jeong, Hei-Cheul Jeung, Jihye Shin, Sang Chul Kim, Sung Hoon Noh, Hyun Cheol Chung, and Sun Young Rha, Clin Cancer Res 11: 612-620, 2005
  • 57. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Sun Young Rha, Yong Hwa Moon, Hei Chul Jeung, Yong Tae Kim, Joo Hyuk Sohn, Woo Ick Yang, Chang Ok Suh, Gwi Eon Kim, Jae Kyung Roh, Hyun Cheol Chung. Breast Cancer Res Treat 90:215-221, 2005
  • 58. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Hyun Jung Ji, Sun Young Rha, Hei Cheul Jeung, Sang Hwa Yang, Sung Wham An, Hyun Cheol Chung. Breast Cancer Res Treat, 93:227-236, 2005
  • 59. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin, and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. YW Moon, SY Rha, HC Jeung, WI yang, CO Suh, HC Chung. Ann Oncol, 16:1778-1785, 2005
  • 60. Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. Shim WY, Park KH, Jeung HC, Kim YT, Kim TS, Hyung WJ, An SH, Yang SH, Noh SH, Chung HC, Rha SY. Int J Mol Med. 16:857-863, 2005
  • 61. Systematic analysis of cDNA microarray-based CGH. Park CH, Jeong HJ, Choi YH, Kim SC, Jeong HC, Park KH, Lee GY, Kim TS, Yang SW, Ahn SW, Kim YS, Rha SY, Chung HC. Int J Mol Med. 17:261-7, 2006
  • 62. A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. Jeung HC, Rha SY, Kim YT, Noh SH, Roh JK, Chung HC. Oncology 70:63-70, 2006
  • 63. Intermediate dose 5-fluorouracil-induced encephalopathy. Kim YA, Chung HC, Choi HJ, Rha SY, Seong JS, Jeung HC. Jpn J Clin Oncol 36:55-59, 2006
  • 64. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. Rha SY, Jeung HC, Yanh WI, Kim JJ, Oh TJ, An SW, Chung HC. Oncol Rep. 15:749-55, 2006
  • 65. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.Woo Sun Kwon, Sun Young Rha,Yeon Ho Choi, Jung Ok Lee, Kyu Hyun Park, Jae Joon Jung, Tae Soo Kim, Hei-Cheul Jeung and Hyun Cheol Chung. Pharamcogenet Genomics 16:429-438, 2006
  • 66. Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: a case report and review of the literature. Jong Chan Youn, Yumie Rhee, Soo Young Park, Won Ho Kim, Soo Jung Kim, Hyun Cheol Chung, Soon Won Hong, Sung-Kil Lim. Endo J 53:339-343, 2006
  • 67. Activation of hypoxia-inducible factor 1a is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Jangsoon Lee, Soon Young Park, Eun Kyung Lee, Chang Gyo park, Hyun Cheol Chung, Sun Young Rha, Yong Kee Kim, Gyu-Un Bae, Bum Kyeong Kim, Jeung-Whan Han, Hoi Young Lee. Clin Cancer Res 12:6351-6358, 2006
  • 68. A phase II trials of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. HC Jeung, SY Rha, BC Cho, NC Yoo, JK Roh, WJ Roh, HC Chung, JB Ahn. Br J Cancer 95:1637-1641, 2006
  • 69. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer. A 15-year experience at a single institute. BC Cho, HC Jeung, HJ Choi, SY Rha, WJ Hyung, JH Cheong, SH Noh, HC Chung. J Surg Oncol 95:461-468, 2007
  • 70. Identification of genes with correlated pattern of variations in copy change and expression in gastric cancer. Sang Hwa Yang, Hei-Cheul Jeung, Ha Jin Jeong, Yeon Ho Choi, Ji Eun Kim, Jae-Joon Jung, Sun Young Rha, Woo Ick Yang, Hyun Cheol Chung Genomics 89:451-459, 2007
  • 71. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Jeung HC, Rha SY, Noh SH, Roh JK, Chung HC. Cancer Chemother Pharmacol. 59:313-320, 2007
  • 72. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).Yeo W, Boyer M, Chung HC, Ong SY,Lim R, Zee B, Ma B, Lam KC, Mo FK, Ho R, Clarke S, Roh JK, Beale P, Rha SY, Jeung HC, Soo R, Goh BC, Chan AT.Cancer Chemother Pharmacol. 59:295-300, 2007
  • 73. A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. NK Kim, SH Baik, BS Min, HR Pyo, YJ Choi, HG Kim, JS Seong, KC Keum, SY Rha, HC Chung, Int J Radiat Oncol Biol Phys 67:204-210, 2007
  • 74. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Yong Wha Moon, Hei Cheul Jeung, Sun Young Rha, Yeon Ho Choi, Woo Ick Yang, Hyun Cheol Chung. Breast Cancer Res Treat 104:31-37, 2007
  • 75. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ. Biochem Biophys Res Commun. 356: 232-238, 2007
  • 76. Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on microarray-CGH. SH Kang, CH Park, HC Jeung, KY Kim, SY Rha, HC Chung. Int J Mol Med 19:901-908, 2007
  • 77. Multi-institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetics and Pharmacogenomic Evaluations. Hei-Cheul Jeung, Sun Young Rha, Hoon Kyo Kim, Ho Young Lim, Samyong Kim, Si Young Kim, Soo Jeong Gong, Chan Hee Park, Joong Bae Ahn, Sung Hoon Noh, Hyun Cheol Chung Oncologist 12:543-554, 2007
  • 78. An Association Between RRM1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients Sun Young Rha, Hai Cheul Jeung, Yeon Ho Choi, Woo Ick Yang, Jin Ho Yoo, Byung Soo Kim, Jae Kyung Roh, Hyun Cheol Chung , Oncologist 12:622-630, 2007
  • 79. Molecular basis of the differences between normal tumor tissues of gastric cancer. Yang S, Shin J, Park KH, Jeung HC, Rha SY, Noh SH, Yang WI, Chung HC. Biochem Biophys Acta-Molecular Basis of Disease 1772:1033-1040, 2007
  • 80. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, Kim NK, Chung HC, Rha SY. Int J Cancer 121:2005-2012, 2007
  • 81. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean Institute Moon YW, Jeung HC, Rha SY, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Ann Surg Oncol 14: 2730-2737, 2007
  • 82. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, Kim H, Pyo HR, Rha SY, Chung HC. Surg Today 37:455-459, 2007
  • 83. Cetuximab rescues a patient with non-small cell lung cancer from rapid disease prrgression during chemotherapy. Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Pyo JY, Roh JK. Acta Oncol 46:547-549, 2007
  • 84. Novel and simple transformation algorithm for combining microarray data sets. Ki Yeol Kim, Dong Hyuk Ki, Ha Jin Jeong, Hei Cheul Jeung, Hyun Cheol Chung, Sun Young Rha. BMC Bioinformatics 8:218, 2007
  • 85. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. HC Jeung, SY Rha, SJ Shin, JB Ahn, SH Noh, JK Roh, HC Chung Brit J Cancer 97:458-463, 2007
  • 86. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. Jung JJ, Jeung HC, Lee JO, Kim TS, Chung HC, Rha SY. Oncol Rep 18:593-599, 2007
  • 87. Bilateral breast cancer: Differential diagnosis using histological and biological parameters. Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC. Jpn J Clin Oncol 37:482-492, 2007
  • 88. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. Gui Youn Lee, Woo Ick Yang, Hei Cheul Jeung, Sang Chul Kim, Min Young Seo, Chan Hee Park, Hyun Cheol Chung, Sun Young Rha. BMC Genomics 8:305, 2007
  • 89. Ixabepilone plus capecutabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Eva S Thomas, Henry L Gomez, Rubi K Li, Hyun Cheol Chung, Luis E Fein, Valorie F Chan, Jacek Jassem, Xavier B Pivot, Judith V Klimovsky, Fernando Hurtado Mendoza, Binghe Xu, Mario Campone, Guillermo L lerzo, Ronald A Peck, Pralay Mukhopadhyay, Linda T Vahdat, Henri H Roche. J Clin Oncol 25:5210-5217, 2007
  • 90. Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-linear RNA. Shin JH, Park CH, Yang YJ, Kim SC, Seo MY, Yang SH, Cho SB, Chung HC, Rha SY. Int J Mol Med 20:905-912, 2007
  • 91. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BC Cho, JB Ahn, JS Seong, JK Roh, HC Chung, JH Sohn, NK Kim. BMC Cancer 8:8, 2008
  • 92. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, Rha SY, Chung HC, Roh JK Cancer Chemother Pharmacol. 61:75-81, 2008
  • 93. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, Rha SY, Yoo NC, Roh JK, Chung HC. Cancer Chemother Pharmacol. 1;157-165, 2008
  • 94. Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, Rha SY, Lee MY, Ro J. Breast Cancer Res Treat 108: 241-250: 2008
  • 95. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low dose leucovorin for advanced gastric cancer. Chong Kun Lim, Hei Cheul jeung, Sun Yooung Rha, Nae Choon Yoo, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Cancer Chemother Pharmacol 61:315-321, 2008
  • 96. Novel biomarker candidates for gastric cancer. Sanghwa Yang, Hyun Cheol Chung Oncology Rep 19:675-680, 2008
  • 97. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin and polyadenylic polyuridylic acid (poly AU) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. HC Jeung, YW Moon, SY Rha, NC Yoo, JK Roh, SH Noh, JS Min, BS Kim, HC Chung Ann Oncol 19:520-526, 2008
  • 98. Phase II study of combination chemotherapy of 5-fluorouracil, low dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. J Jeong, HC Heung, SY Rha, CK Im, SJ Shin, JB Ahn, SH Noh, JK Roh, HC Chung. Ann Oncol 19:1135-1140, 2008
  • 99. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastasis. SH Cheon, SY Rha, HC Jeung, CK Im, SH Kim, HR Kim, JB Ahn, JK Roh, SH Noh, HC Chung. Ann Oncol 19:1146-1153, 2008
  • 100. Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. Ki Yeol Kim, Dong Hyuk Ki, Hei Cheul jeung, Hyun Cheol Chung, Sun Young Rha BMC Bioinformatics 9:283, 2008
  • 101. Pemetrexed and cisplatin in patients with advanced gastric cancer: A Korean Cancer Study Group (KCSG) multicenter phase II study. Kim Yeul, Chung Hyun Cheol, Kang Won Ki, Park Sook Ryun, Kim Chul Soo, Kim Tae Yue, Shin Sang Won, Park Byung Joo, Cha Soo Jin, Bang Yung Jue. Cancer Chemother Pharmacol 62:263-270, 2008
  • 102. Standardization of the Korea version of Mini-Mental Adjustment to cancer (K-Mini-MAC) scale: factor structure, reliability and validity. Kang JI, Chung HC, Kim SJ, Choi HJ, Ahn JB, Jeung HC, Namkoong K. Psychooncology 17:592-597, 2008
  • 103. Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Nae Choon Yoo, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung. Cancer Lett 270:269-276, 2008
  • 104. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Choi HJ, Kim NK, Keun KC, Cheon SH, Shin SJ, Baik SH, Cheon JH, Rha SY, Roh JK, Jeung HC, Chung HC, Ahn JB. Radiother Oncol 87:361-366, 2008
  • 105. Variation of the 3’ telomeric overhang lengths in human cells. Lee ME, Rha SY, Jeung HC, Kim TS, Chung HC, Oh BK. Cancer Lett 264:107-118, 2008
  • 106. Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. Yu EJ, Lee Y, Rha SY, Kim TS, Chung HC, Oh BK, Yang WI, Noh SH, Jeung HC. Mol Cancer Res 6:1554-1566, 2008
  • 107. Cyclo-oxygenase-2 expression in pretreatment biopsy as a predictor of tumor response after preoperative chemoradiation in rectal cancer Min BS, Choi YJ, Pyo HR, Kim H, Seong J, Chung HC, Rha SY, Kim NK Arch Surg 143:1091-1097, 2008
  • 108. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Cancer Res 68:4277, 4286, 2008
  • 109. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, Rha SY. Genomics 93:52-61, 2009
  • 110. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Sang Gyu Lee, Young Geon Jee, Hyun Cheol Chung, Sung Bae Kim, Jungsil Ro, Young Hyuck Im, Seock Ah Im, Jae Hong Seo. Breast Cancer Res Treat 114:589-595, 2009
  • 111. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assesment of medical literature of randomized controlled trials. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. Cancer Chemother Pharmacol 63:912-927, 2009
  • 112. Association of the ABCB1 gene polymorphism 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Hyun Chang, Sun Young Rha, Hei Cheul Jeung, Chong Kun Im, Joong Bae Ahn, Woo Sun Kwon, Nae Choon Yoo, Jae Kyung Roh, Hyun Cheol Chung Ann Oncol 20:272-277, 2009
  • 113. A multi-center phase II study of S-1 plus paclitaxel as first ?line therapy for patients with advanced or recurrent unresectable gastric cancer. Jae Jin Lee, Si-Young Kim, Hyun Cheol Chung, Kyung hee Lee, Hong Suk Song, Won Ki Kang, Young Seon Hong, In Sil Choi, Young Yeul Lee, In Sook Woo, Jin Hyuk Choi. Cancer Chemother Pharamcol 63:1083-1090, 2009
  • 114. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. Oh SJ, Hyung WJ, Li C, Song J, Rha SY, Chung HC, Choi SH, Noh SH. J Gastroenterol Hepatol 24:475-479, 2009
  • 115. Copy number changes can be a predictor for hemoglobin-reduction after S-1 monotherapy in gastric cancer. . Hei Cheul Jeung, Sun Young Rha, Chan Hee Park, Chong-Kun Im, Sang Joon Shin, Joong Bae Ahn, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Int J Oncol 34:787-796, 2009
  • 116. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Woo Sun Kwon, Sun Young Rha, Hei Cheul Jeung, Joong bae Ahn, Jae Joon Jung, Sung Hoon Noh, Hyun Cheol Chung. Cancer Lett 277:155-163, 2009
  • 117. Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. Sun Young Rha, Hei Cheul Jeung, Min Young Seo, Sang Cheol Kim, Woo Ick Yang, Yong Wha Moon, Hyun Cheol Chung. Int J Oncol 34:837-846, 2009
  • 118. Expression of anaphase-promoting complex 7 in fibroadenomas and phylloides tumors of breast. Yup Kang, Jang Hee Kim, Tae Hui Lee, Tai Seung Kim, Woo Hee Jung, Hyun Cheol Chung, Byeong Woo Park, Seung Soo Sheen, Jae Ho Han. Hum Pathol 40: 98-107, 2009
  • 119. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. Oh SJ, Hyung WJ, Li C, Song J, Kang W, Rha SY, Chung HC, Choi SH, Noh SH. J Surg Oncol 99:275-280, 2009
  • 120. Subtelomeric DNA methylation and telomere length in human cancer cells. Myung Eun Lee, Sun Young Rha, Hei Cheul Jeung, Hyun Cheol Chung, Bong Kyeong Oh. Cancer Letters 281:82-91, 2009
  • 121. Prediction of recurrence of early gastric cancer after curative resection. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Rha SY, Chung HC, Choi SH, Wang LB, Noh SH. Ann Surg Oncol 16:1896-1902, 2009
  • 122. Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer. Kim M, Chung HC. J Cancer Res Clin Oncol 135:1501-1512, 2009
  • 123. Increment of a-dystroglycan expression in liver metastasis correlates with poor survival in gastric cancer. Yong Wha Moon, Sun Yougn Rha, Xianglan Zhang, Hei-Cheul Jeung, Woo Ick Yang, Obin Kwon, Jae Heon Jeong, Sung Hah Cheon, Nae Choon Yoo, Hyun Cheol Chung. J Surg Oncol 100:459-465, 2009
  • 124. Changes of telomerase activity by alternative splicing of full-length and β variants of hTERT in breast cancer patients. Sun Young Rha, Hei Cheul Jeung, Kyu Hyun Park, Jin Ju Kim, and Hyun Cheol Chung. Oncol Res 18:213-220, 2009
  • 125. A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. Chong Kun Im, Sun Young Rha, Hei Cheil Jeung, Jaeheon Jeong, Soo Hyeon Lee, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Oncology 77:349-357, 2009
  • 126. A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. Ki Yeol Kim, Hyun Cheol Chung, Sun Young Rha. J Biosci Bioeng 108:252-258, 2009
  • 127. Identification of significant regional genetic variations using continuous CNV values in aCGH data. Gui Youn Lee, Jin Kim, Hei-Cheul Jeung, Hyun Cheol Chung, Sun Young Rha, Ki-Yeol Kim. Genomics 94:317-323, 2009
  • 128. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. CH Ooi, T Ivanova, J Wu, M Lee, IB Tan, J Tao, L ward, JH Koo, V Gopalakrishnan, Y Zhu, LL Cheng, J Lee, SY Rha, HC Chung, K Ganesan, J So, KH Soo, D Lim, WH Chan, WK Wong, D Bowtell, KG Yeoh, H Grabsch, A Boussioutas, P Tan. PloS Genetics 5 e1000676, 2009
  • 129. Activity of ixabepilone in oestrogen receptor-negative and ostrogen receptor-progesterone receptor-hyman epidermal growth factor receptor 2-negative metastatic breast cancer. Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mondoza FH, Mukhopadyay P, Roche HH. Eur J Cancer 45:2940-2946, 2010
  • 130. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyung Soo Park, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung Invest New Drugs 28:650-658, 2010
  • 131. Circulating Endothelial Progenitor Cells (EPC) for Tumor Vasculogenesis in Gastric Cancer Patients. Joong Bae Ahn, Sun Young Rha, Sang Joon Shin, Hei-Cheul jeung, Tae Soo Kim, Xianglan Zhang, Kyu Hyun Park, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung. Cancer Letters 288:124-132, 2010
  • 132. A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. Chong Kun Im, Sun Young Rha, Hei Cheul jeung, Joong Bae Ahn, Sang Joon Shin, Sung Hoon Noh, Jae Kyung Roh, Hyun Cheol Chung, Am J Clin Oncol 33;56-60, 2010
  • 133. Two doses of oral fluoropyrimidines S-1 of 35mg/m2 and 40mg/m2 bid: comparison of pharmacokinetic profiles in Korean patients with advanced gastric cancer. Hei Cheul Jeung, Sun Young Rha, Sang Joon Shin, Joong Bae Ahn, Sugng Hoon Noh, Jae Kyung Rog, Hyun Cheol Chung. Jpn J Clin Oncol 40:29-35, 2010
  • 134. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. Minkyu Jung, Hei Cheul Jeung, Sung Sook Lee, Jun Yong Park, Soojung hong, Soo Hyeon Lee, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha. J Cancer Res Clin Oncol 136:517-526,2010
  • 135. Outcomes of multiple slavage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design, YH Moon, SY Rha, HC Jeung, C Kim, MH Hong, H Chang, JK Roh, SH Noh, BS Kim, HC Chung, Cancer Chemother Pharmacol 66:797-805, 2010
  • 136. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Hyun Chang, Sun Young Rha, Hei Cheul Jeung, Chong Kun Im, Sung Hoon Noh, Jin Ju Kim, Hyun Cheol Chung Oncology Reports 23: 271-278, 2010
  • 137. A comparative study of protein expressions in primary colorectal cancer and synchronous hepatic metastases: The significance of MMP-1 expression as a predictor of liver metastasis. Kim, Ko, Kim, Chung, Min, Lee, Park, Kim. Scandinavian J Gastroenterol 45:217-225, 2010
  • 138. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. Hye Ryun Kim, Seong Ha Cheon, Kwang Hun Lee, Jung Ryun Ahn, Hei Cheul Jeung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha. Int J Hyperthermia 26:305-315, 2010
  • 139. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Jae Jun Jung, Tae Soo Kim, Ho Jeong Kwon, Byung Soo Kim, Hyun Cheol Chung J Cancer Res Clin Oncol 136;1901-1913, 2010
  • 140. Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. Chan Hee Park, Sun Young Rha, Hei Cheul Jeung, Seung Hui Kang, Dong Hyuk Ki, Won Suk Lee, Sung Hoon Noh, Hyun Cheol Chung. J Surg Oncol 102:454-461, 2010
  • 141. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roche HH. Breast Cancer res Treat 122:409-418, 2010
  • 142. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Jeung HC, Rha SY, Roh JK, Chung HC, Ahn JB. Radiother Oncol 95:303-307, 2010
  • 143. Paclitaxel combined with ifosfamide in anthracycline and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. YW Moon, JH Sohn, HJ Choi, H Chang, BW Park, SI Kim, SH Park, JS Koo, YT Kim, JK Roh, HC Chung, JH Kim. Cancer Chemnother Pharmacol 66:425-431, 2010
  • 144. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Chen JS, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myand SP, Mullaney BP, Shen LJ, Linn C. Anti-Cancer Drugs 21:777-784, 2010.
  • 145. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with longterm follow-up. Jung M, Shun HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. Ann Surg Oncol 17:3259-3268, 2010.
  • 146. Is pyridozine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine? HC Jeung and HC Chung. Asia Pac J Clin Oncol 6:141-143: 2010.
  • 147. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Eoh JK, Chung HC, Rha SY. Cancer Sci 101:2200-2206, 2010.
  • 148. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase III open-label, randomized controlled trial. Bang YJ, Van Custem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, ToGA trial investigators. Lancet 376;687-697, 2010.
  • 149. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Invest New Drugs 29:1449-1458, 2011
  • 150. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Chnag H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC. Breast Cancer Res Treat 125:55-63, 2011
  • 151. A randomized phase II study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. Cancer 117:2050-2057, 2011
  • 152. Prevalence and associated factors of psychological distress among Korean cancer patients. Kim SJ, Rha SY, Song SK, Namkoong K, Chung HC, Yoon SH, Kim GM, Kim KR. Gen Hosp Psychiatry 33:246-252, 2011
  • 153. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) is previously treated patients with adfvanced gastric cancer. Hong Jae Chon, Sun Young Rha, Hyung Soon Park, Sang Joon Shin, Hyo Song Kim, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung, Hei Cheul Jeung. Cancer Chemother Pharmacol 68:991-999, 2011
  • 154. Predictive value of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK, Noh SH, Chung HC. Anticancer Drugs 22:801-810, 2011
  • 155. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, Chung HC, Park BW. J Cancer Res Clin Oncol 137:1123-1130, 2011
  • 156. A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. Park HS, Rha SY, Kim HS, Hyung WJ, Park JS, Chung HC, Noh SH, Jeung HC. Oncology 80:142-150, 2011
  • 157. Biweekly gemcitabine-paclitaxel, gencitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial. Binghe Xu, Zefei Jiang, SB Kim, Shiying Yu-Jifeng Feng, Artur Malzyner, Auro del Giglio, HC Chung, Li Jun Shen, Daniel Lee Kay Pen. Breast Cancer 18:203-212, 2011
  • 158. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. HS Kim, MH Hong, KE Kim, SJ Shin, JN Ahn, HC Jeung, HC Chung, YG Koh, SH Lee, YJ Bang, SY Rha. Oncology 80:395-405, 2011
  • 159. DNA methylation predicts recurrence from resected stage III proximal colon cancer. JB Ahn, WB Chung, Osamu Maeda, SJ Shin, HS Kim, HC Chung, NK Kim, Jean-Pierre Issa. Cancer 117:1847-1854, 2011.
  • 160. CD44-SLC1A2 gene fusions in gastric cancer. J Tao, NT Deng, K Ramnarayanan, B Huang, HK Oh, SH Leong, SS Lim, IB Tan, CH Ooi, J Wu, M Lee, S Zhang, SY Rha, HC Chung, DT Smoot, H Ashktorab, OL Kon, V Cacheux, C Yap, N Palanisamy, P Tan. Sci Transl Med 3:1-11, 2011.
  • 161. Treatment of recurrent heparocellular carcinoma after liver transplantation. Kim HR, Cheon SH, Rha SY, Lee S, Han HK, Chon SY, Lee JD, Sung JS, Chng HC. Asia Pac J Clin Oncol 7:258-269, 2011
  • 162. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, Rha SY. Oncol Rep 25:717-727, 2011
  • 163. MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. Hepatogastroenterology. 58:2015-2019, 2011
  • 164. Advanced detection of recent changing trends in gastric cancer survival: Up-to-date comparison by period analysis. Kim HS, Lee H, Jeung HC, Noh SH, Chung HC, Roh JK, Nam CM, Rha SY. Jpn J Clin Oncol 41:1344-1350, 2011
  • 165. Methylation status of lamin A/C in gastric cancer cell lines. Lee WS, Jung JJ, Jeung HC, Noh SW, Oh BK, Kim KY, Kim TS, Chung HC, Roh JK, Rha SY. Hepatogastroenterology 59:115-116, 2011
  • 166. A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures Ooi CH, Oh HK, Wang HZ, Tan AL, Wu J, Lee M, Rha SY, Chung HC, Virshup DM, Tan P. PLoS Genet e1002415, 2011
  • 167. Adjuvant capecutabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzen F, Noh SH; CLASSIC trial investigators. Lancet 379:315-321, 2012
  • 168. A randomized phase II trial of S1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC. Eur J Cancer 48:518-526, 2012.
  • 169. A pilot study of S1 plus cisplatin versus 5-fluorouracil plus cisplatin for post-operative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, Rha SY. Invest New Drugs 30:357-363, 2012
  • 170. A phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. SJ Shin, JB Ahn, KS park, YJ Lee, YS Hong, TW Kim, HR Kim, SY Rha, JK Roh, DH Kim, C Kim, HC Chung. Invest New Drug 30:672-680, 2012
  • 171. Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Kim KR, Chung HC, Lee E, Kim SJ, Namkoong K. Support Care Cancer 20:2177-2182, 2012
  • 172. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. SW Lee, TJ Oh, HC Chung, SY Rha, CG Kim, YH Moon, BD Hoehn, DJ Jeong, SH lee, NK Kim, CH Park, MA Yoo, SW An. Int J Oncol, 40:889-898, 2012
  • 173. FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. JI Kang, HC Chung, HC Jeung, SJ Kim, SK An, K Namkoong. Psychoneuroendocrinol 37: 1569-1576, 2012
  • 174. Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phosphor-specific flow cytometry. Lim SM, Hwang JW, Bae SK, Bae SH, Ahn JB, Rha SY, Roh JK, Chung HC, Shin SJ. Anal Quant Cytol Histol 34:309-316, 2012
  • 175. A phase I pharmacokinetic study of TSU-68 ( a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. Invest New Drugs 30:1501-1510, 2012
  • 176. AMPKα Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer. Yon Hui Kim, Han Liang, Xiuping Liu, Ju-Seog Lee, Jae Yong Cho, Jae-Ho Cheong, Hoguen Kim,Min Li, Thomas J. Downey, Matthew D. Dyer, Yongming Sun, Jingtao Sun, Ellen M. Beasley, Hyun Cheol Chung, Sung Hoon Noh, John N. Weinstein, Chang-Gong Liu, Garth Powis. Cancer Res. 72:2512-21, 2012.
  • 177. High level of serum VEGF and TIMP-2 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection. Byung Soh Kim, Nam Kyu Kim, Hee Cheul Jeong, Hyun Cheol Chung. Oncol Lett 4: 123-130, 2012
  • 178. Identification of radiosensitvity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. HS Kim, SC Kim, SJ Kim, CH Park, HC Jeung, YB Kim, JB Ahn, HC Chung, SY Rha. BMC Genomics 13;348, 2012
  • 179. Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter cross-sectional study. Oh DY, Crawford B, Kim SB, Chung HC, McDonald J, Lee SY, Ko SK, Ro J. Asia Pac J Clin Oncol 8:232-291, 2012
  • 180. Overexpression of class III beta tubullin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. PLoS One 7:e4517, 2012
  • 181. Epigenetic therapyusing belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the Cancer Therapeutics Research Group. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. J Clin Oncol 30:3361-3367, 2012
  • 182. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riaha S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yang WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. Gut 61:673-684, 2012
  • 183. Application of the Western-based adjuvant online model to Korean colon cancer patients: a single institution experience. Jung M, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. BMC Cancer 12:471, 2012
  • 184. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with anti-angiogenic agent. Shin SJ, Hwang JW, Ahn JB, Rha SY, Roh JK, Chung HC. Invest New Drug 31:1-13, 2013
  • 185. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. Kim YB, Jeung HC, Jeong I, Lee K, Rha SY, Chung HC, Kim GE. J Radiat Res 54:52-60, 2013
  • 186. Changing treatment patterns in elderly patients with resectable colon cancer. Kim GM, Ahn JB, Rha SY, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. Asia Pac J Clin Oncol 9:265-272, 2013
  • 187. Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Kim HS, Shin SJ, Kim SC, An S, Rha SY, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer 21:1751-1759, 2013
  • 188. Randomized dose finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell CJ, Rhee BG, Patt R, Hwang TH, Kirn DH. Nat Med 19: 329-336, 2013
  • 189. Telomerase- and angiogenesis-related gene response to irradiation in human umbilical vein endothelial cells. Hyun Chang, Sun Young Rha, Hei-Cheul Jeung, Kyu Hyun Park, Tae Soo Kim, Yong bae Kim, Hyun Cheol Chung Int J Mol Med 31:1202-1208, 2013.
  • 190. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin-A treatment. Jung AR, Yoo JE, Shim YH, Choi NH, Jeung HC, Chung HC, Rha SY, Oh BK. Anticancer Res 33:821-829, 2013
  • 191. Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Minkyu Jung, Eun Hee Choi, Chung Mo Nam, Sun Young Rha, Hei Cheul Jeung, Soo Hyun Lee, Woo Ick Yang, Jae Kyung, Roh & Hyun Cheol Chung. Ann Surg Oncol 20:2615-2624, 2013
  • 192. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an onservational study. Kim KY, Cha IH, Ahn JB, Kim NK, Rha SY, Chung HC, Roh JK, Shin SJ. J Surg Oncol 107:613-618, 2013
  • 193. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomized, open-label phase 3 trial. Lord F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, park JO, Sawaki A, Celik I, Gotte H, Melezinkova H, Moehler M: Arbeitsgemeinschaft Internisttische Onkologie (AIO) and EXPAND Investigators. Lancet Oncol 14:490-499, 2013
  • 194. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. TJ Oh, NY Kim, YH Moon, MS Kim, BD Hoehn, CH Park, TS Kim, NK Kim, HC Chung, SW An. J Mol Diag 15:1-10, 2013
  • 195. Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells. Lim SM, Hwang JW, Ahn JB, Bae SK, Park CH, Kim KY, Rha SY, Chung HC, Roh JK, Shin SJ. Anticancer Res 33:2499-2508, 2013.
  • 196. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Lee YK, Jun HJ, Nahm JH, Lim TS, Park JS, Ahn JB, Rha SY, Chung HC, Oh HE, Song JS, Yang WI, Kim HS. Jpn J Clin Oncol 43: 996-1003, 2013.
  • 197. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. BMC Cancer 13;394, 2013.
  • 198. Everolimus for previously treated advanced gastric cancer; results of the randomized double-blind phase III GRANITE-1 study. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Custem E. J Clin Oncol 31:3935-3943, 2013.
  • 199. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. Kim SH, Shin SJ, Lee KY, Kim H, Kim TI, Kang DR, Hur H, Min BS, Kim NK, Chung HC, Roh JK, Ahn JB. Ann Surg Oncol 20:3407-3413, 2013.
  • 200. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. Ann-Lii Cheng, Yoon-Koo Kang, Deng-Yn Lin, Joong-Won Park, Masatoshi Kudo, Shukui Qin, Hyun-Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi, Masao Omata, Susan Pitman Lowenthal, Silvana Lanzalone, Liqiang Yang, Maria Jose Lechuga and Eric Raymond. J Clin Oncol 31:4067-4075, 2013
  • 201. S-1 combined with docetaxel following doxorubicin plus cyclophoisphamide as neoadjuvant therapy in breast cancer: phase II trial. Moon YW, Lee S, Park BW, Kim EK, Kim SI, Koo JS, Park S, Kim MJ, Chung HC, Kim JH, Sohn J. BMC Cancer 13:583, 2013
  • 202. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Koizumi W, Kim YH, Fuji M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inoguchi M, Tanabe K, Okuno T, Ogura M, Ypshida K, Takeuchi M, Nakajima T; The JACCRO and KCSG Study Group. J Cancer Res Clin Oncol 140: 319-328, 2014
  • 203. Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy. Lee SH, Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Asia Pac J Clin Oncol. 10:237-245, 2014
  • 204. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. Invest New Drugs. 32;561-568, 2014
  • 205. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. Zhang X, Zheng Z, Shin YK, Kim KY, Rha SY, Noh SH, Chung HC, Jeung HC. Pathology 46:316-24, 2014.
  • 206. Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial. Kim SB, Yoo C, Ro J, Im SA, Im YH, Kim JH, Ahn JH, Jung KH, Song HS, Kang SY, Park HS, Chung HC. Invest New Drugs 32: 753-776, 2014
  • 207. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER-2 amplified advanced gastric cancer in Asian populations: Tytan-a randomizedm phase III study. Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang, Hiroto Miwa, Shu-Kui Qin, Ik Joo Chung, Kun-Huei Yeh, Ji-Feng Feng, Akihira Mukaiyama, Mikiro Kobayashi, Atsushi Ohtsu, Yung-Jue Bang. J Clin Oncol 32:2039-2049, 2014
  • 208. Quallity of life in the trastuzumab for gastric cancer trial. Taroh Saito, Yung-Jue Bang, Evgeny A. Gotovkin, Yasuo Hamamoto, Yoo-Koo Kang, Vladimir M. Moiseyenko, Atsushi Ohtsu, Eric Van Custem, Nedal Al-Sakaff, Alexa Urspruch, Julie Hill, Harald A. Webner, Hyun Cheol Chung. The Oncologist 19:1-8, 2014
  • 209. Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer. Koh MJ, Jeung HC, Namkoong K, Chung HC, Kang JI. J Psychosom Res 77:76-80, 2014
  • 210. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. JS Park, HC Jeung, SY Rha, JB Ahn, BD Kang, HJ Chon, MH Hong, ST Lim, WI yang, CM Nam, HC Chung. Cancer Chemother Pharmacol 74:799-808, 2014
  • 211. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. Ha Young Lee, Joong Bae Ahn, Sun Young Rha, Hyun Cheol Chung, Kyu Hyun Park, Tae Soo Kim, Nam Kyu Kim, Sang Joon Shin. World J Surg Oncol 12: 232-238, 2014
  • 212. The effect of dysintegrin-metalloproteinase ADAM9 in gastric cancer progression. Kim JM, Jeung HC, Rha SY, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G. Mol Cancer Ther 13:3074-3085, 2014
  • 213. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomized phase 3 trial. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, JI J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial invesstigators. Lancet Oncol 15:1389-1396, 2014.
  • 214. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. HS Park, MK Jung, HS Kim, HI Kim, JY An, JH Cheong, WJ Hyung, SH Noh, YI Kim, HC Chung, SY Rha. Ann Surg Oncol 22:224-231, 2015
  • 215. PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Xianglan Zhang, Ji Soo Park, Kyu Hyun Park, Ki Hyang Kim, Minkyu Jung, Hyun Cheol Chung, Sun Young Rha, Hyu Song Kim. Oncology 88:76-85, 2015
  • 216. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Park CH, Rha SY, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. Int J Cancer 136:2273-2283, 2015
  • 217. Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Oncology 88:147-156, 2015
  • 218. LAMC2 enhances the metastatic potential of lung adenocarcinoma. YW Moon, G Rao, JJ Kim, HS Shim, KS Park, SSAn, B Kim, PS Steeg, S Sarfaraz, L Changwoo Lee, Donna Voeller, EY Choi, Li Luo, D Palmieri, HC Chung, JH Kim, Y Wang, G Giaccone. Cell Death Diff 1:1-12, 2015
  • 219. Dovitinib (TK1258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. CK Lee, ME Lee, WS Lee, KM Kim, KH Park, TS Kim, KY Lee, JB Ahn, HC Chung, SY Rha. Am J Cancer Res 5:72-86, 2015
  • 220. Ramurcirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomized double-blind, multicenter, phase 3 trial. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M: REACH trial Lancet Oncol 16:859-70, 2015
  • 221. Signatures of tumorimmunity distinguish Asian and non-Asian gastric adenocarcinomas. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Yistra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Gut 64:1721-1731, 2015
  • 222. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. CK Lee, MK Jung, IK Jung, SJ Heo, YH Jeong, JY An, HI Kim, JH Cheong, WJ Hyung, SH Noh, HS Kim, SY Rha, HC Chung. Ann Surg 263:96-102, 2016
  • 223. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Hong Jae Chon, Hye Ryun Kim, Eunah Shin, Chan Kim, Su Jin Heo, Choong-kun Lee, Jin Kyu Park, Sung Hoon Noh, Hyun Cheol Chung, Sun Young Rha. Ann Surg Oncol 22:3938-3945, 2015
  • 224. Do recent advances in diagnostic and therapeutic procedures negate the benefit of postmastectomy radiotherapy in N1 patients with a low risk of locoregional recurrences? Chang JS, Lee J, Kim KH, Sohn JH, Kim SI, Park BW, Chung HC, Keum KC, Suh CO, Kim YB. Medicine 94:e1259, 2015
  • 225. Lapatinib in combination with capecitabine plus oxaliplatin inn human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma.: TRIO-013/LOGiC ? a randomized phase III trial. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk K, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houe V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. JCO 10:443-451, 2016
  • 226. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples. Zhu Y, Lu D, Lira ME, Xu Q, Du Y, Xiong J, Mao M, Chung HC, Zheng G. Exp Mpl Pathol 100:287-293, 2016
  • 227. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. Oncotarget. 16;7:8055-8066, 2016.
  • 228. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. Ann Nucl Med. 30:279-286, 2016.
  • 229. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC. Oncotarget 7:10547-10556, 2016.
  • 230. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Lancet Oncol. 17:717-26, 2016.
  • 231. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia.Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, Rha SY, Noh SH, Jeung HC. Ann Surg 265:946-953, 2017
  • 232. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. Min Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, Koji Kono, Abhishek Gupta, You Bin Lin, Kousaku Mimura, Jean Paul Thiery, Boon Cher Goh, Patrick Tan, Ross Soo, Cheng William Hong, Lingzhi Wang, Suling Joyce Lin, Elya Chen, Sun Young Rha, Hyun Cheol Chung, Jie Li, Sayantani Nandi, Hiu Fung Yuen, Shu-Dong Zhang, Yeoh Khay Guan, Jimmy So, and Qi Zeng JCI Insight 1:e87607, 2016
  • 233. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H.Oncotarget. 7:44608-44620, 2016
  • 234. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. BMC Cancer. 8;16:434, 2016.
  • 235. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Park JS, Chon HJ, Jeung HC, Shin SJ, Rha SY, Ahn JB, Lee KY, Kim NK, Chung HC.J Cancer Res Clin Oncol. 142:2051-2059, 2016
  • 236. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Chow LQ, Haddad R, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee S-H, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin C-C, Chung HC, Meister A, Dolled-Fillhart M, Pathiraja K, Cheng JD, Seiwert T. J Clin Oncol. 34:3838-3845, 2016.
  • 237. A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH. Cold Spring Harb Mol Case Stud. 2(5):a000992. doi: 10.1101/mcs.a000992, 2016
  • 238. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Chang SC, Yang L, Abada PB, Chau I. JAMA Oncol. 2016 (in press)
  • 239. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Press MF, Ellis CE, Gagnon RC, Grob TJ, Buyse M, Villalobos I, Liang Z, Wu S, Bang YJ, Qin SK, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. Mol Cancer Ther.16:228-238, 2017..
  • 240. ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC. Biochem Pharmacol.123:73-84, 2017.
  • 241. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer. Park HS, Sohn J, Kim SI, Park S, Park HS, Gho SG, Chung HC, Paik S, Kim GM. Breast Cancer Res Treat 163:255-262, 2017
  • 242. Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. Sohn BS, Kim SB, Ahn JH, Jung KH, Kim J, Lee KS, Ro J, Im SA, Im YH, Song HS, Park HS, Chung HC. Asia Pac J Clin Oncol. 13:365-371, 2017
  • 243. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. HS Kim, HN Lee, SJ Shin, SH Beom, MK Jung, SJ Bae, EY Lee, KH Park, YY Choi, TE Son, HI Kim, JH Cheong, WJ Hyung, JH Park, SK Shin, SK Lee, YC Lee, WS Koom, JS Lim, HC Chung, SH Noh, SY Rha, HK Kim, SM Park. Oncotarget 8:38389-38398, 2017
  • 244. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. HC Jeung, SY Rha, SJ Shin, JB Ahn, KH Park, TA Kim, JJ Kim, JK Roh, HC Chung. Oncology Letters, 14:2385-2392, 2017
  • 245. A Phase 1, Open Label, Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MG1102 (Apolipoprotein(a) Kringle V) in Patients with Solid Tumors. Gun Min Kim, Tony Reid, Sang Joon Shin, Sun Young Rha, Joong Bae Ahn, Sung Sil Lee, Hyun Cheol Chung. Invest New Drugs, 35: 773-781, 2017
  • 246. Trastuzumab emtansine versus taxane use for previously treated HER-2 positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomized open-label adaptive phase 2/3 study. Thuss-Patience PC, Shah MA, Ohtsu A, Custem EV, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, Horst T, Harle-Yge ML, Althaus BL, Kang YK. Lancet Oncology 18:640-653, 2017
  • 247. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Oncotarget 8:31169-31179, 2017
  • 248. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY. BMC Cancer. 2017 17:283. doi: 10.1186/s12885-017-3260-2
  • 249. Modulation of HAT activity by the BRCA2N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC. Biochem Pharmacol. 138: 163-173, 2017
  • 250. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M .Gastric Cancer. 2017 Jun 22. doi: 10.1007/s10120-017-0739-0. [Epub ahead of print]
  • 251. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX. Eur J Cancer 81:17-25, 2017
  • 252. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT. Clin Cancer Res. 23:5981-5992, 2017.
  • 253. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T. Cancer Chemother Pharmacol. 80:1197-1207, 2017
  • 254. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Lancet. 390: 2461-2471, 2017
  • 255. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M. Oncotarget. 8: 61837-61845, 2017.
  • 256. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Chan Kim, Choong-kun Lee, Hong Jae Chon1, Joo Hoon Kim, Hyung Soon Park, Su Jin Heo, Hyun Jeong Kim, Tae Soo Kim, Woo Sun Kwon, Hyun Cheol Chung and Sun Young Rha. Oncotarget 8:113494-113501, 2017.
  • 257. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: analyses from KEYNOTE-012. Tahara M, Muro K, Hasegawa Y, Chung HC, Lin CC, Bhumsuk Keam, Takahashi K, Cheng JD, Bang YJ. Cancer Sci. 2017 Dec 28. doi: 10.1111/cas.13480. [Epub ahead of print]
  • 258. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, Han YD, Chung HC, Kim NK, An S. Clin Epigenetics. 2017 Dec 4;9:126. doi: 10.1186/s13148-017-0426-3. eCollection 2017.
  • 259. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY. Int J Cancer. 2018 Feb 13. doi: 10.1002/ijc.31304. [Epub ahead of print]
  • 260. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS. BMC Cancer 18(1):158, 2018. doi: 10.1186/s12885-018-4066-6.
  • 261. Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. Chung HC, Kok VC, Cheng R, Hsu Y, Orlando M, Fuchs C, Cho JY. Asia Pac J Clin Oncol. 2018 Jan 10. doi: 10.1111/ajco.12829. [Epub ahead of print]
  • 263. A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Sakai D, Chung HC, Oh DY, Park SH, Kadowaki S, Kim YH, Tsuji A, Komatsu Y, Kang YK, Uenaka K, Wijayawardana SR, Wacheck V, Wang X, Yamamura A, Doi T.Cancer Chemother Pharmacol. 80:1197-1207, 2017
  • 264. Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. Makoto Tahara, Kei Muro, Yasuhisa Hasegawa, Hyun Cheol Chung, Chia-Chi Lin, Bhumsuk Keam, Kenichi Takahashi, Jonathan D. Cheng, Yung-Jue Bang. Cancer Sci 109: 771?776, 2018
  • Role of probe-based confocal laser endomicroscopy-targeted biopsy in the molecular and histopathological study of gastric cancer
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 34/1 :84-91,2019
  • S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
    CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019
  • Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials
    CLINICAL BREAST CANCER 18/6 :489-497,2018
  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
    LANCET 392/10142 :123-133,2018
  • Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 22/12 :5,899-5,908,2018
  • Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
    ANTICANCER RESEARCH 38/11 :6,171-6,180,2018
  • Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
    CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018
  • Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Journal of Global Oncology 4/ :1-12,2018
  • MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
    JOURNAL OF SURGICAL ONCOLOGY 117/8 :1,679-1,686,2018
  • Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
    ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018
  • A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
    AAPS JOURNAL 20/4 :72-87,2018
  • Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012
    BRITISH JOURNAL OF CANCER 119/2 :153-159,2018
  • Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
    BRITISH JOURNAL OF CANCER 119/1 :19-26,2018
  • The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
    GASTRIC CANCER 21/2 :213-224,2018
  • Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14/3 :204-209,2018
  • Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor
    INTERNATIONAL JOURNAL OF CANCER 143/1 :151-159,2018
  • Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
    CANCER SCIENCE 109/3 :771-776,2018
  • Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
    BMC CANCER 18/1 :158-165,2018
  • PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
    ONCOTARGET 8/69 :113,494-113,501,2017
  • Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer
    CLINICAL EPIGENETICS 9/1 :126-137,2017
  • A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 80/6 :1,197-1,207,2017
  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
    LANCET 390/10111 :2,461-2,471,2017
  • A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors
    INVESTIGATIONAL NEW DRUGS 35/6 :773-781,2017
  • A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors
    CLINICAL CANCER RESEARCH 23/19 :5,981-5,992,2017
  • Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13/6 :365-371,2017
  • Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
    ONCOTARGET 8/37 :61,837-61,845,2017
  • HER2 status in advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma for entry to the TRIO-013/LOGiC trial of lapatinib
    MOLECULAR CANCER THERAPEUTICS 16/1 :228-238,2017
  • Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer
    ONCOLOGY LETTERS 14/2 :2,385-2,392,2017
  • Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
    EUROPEAN JOURNAL OF CANCER 81/ :17-25,2017
  • Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
    ONCOTARGET 8/24 :38,389-38,398,2017
  • Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines
    BIOCHEMICAL PHARMACOLOGY 138/ :163-173,2017
  • Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    ONCOTARGET 8/19 :31,169-31,179,2017
  • Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
    LANCET ONCOLOGY 18/5 :640-653,2017
  • Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 163/2 :255-262,2017
  • Prevalence and prognostic implications of psychological distress in patients with gastric cancer
    BMC CANCER 17/1 :283-,2017
  • Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia
    ANNALS OF SURGERY 265/5 :946-953,2017
  • ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition
    BIOCHEMICAL PHARMACOLOGY 123/ :73-84,2017
  • A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE 2/5 :a000992-,2016
  • Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
    ONCOTARGET 7/9 :10,547-10,556,2016
  • High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 142/9 :2051-2059,2016
  • Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
    ONCOTARGET 7/28 :44608-44620,2016
  • Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC - A randomized phase III trial
    JOURNAL OF CLINICAL ONCOLOGY 34/5 :443-451,2016
  • Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
    BMC CANCER 16/434 :1-7,2016
  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
    LANCET ONCOLOGY 17/6 :717-726,2016
  • Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
    ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016
  • Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites
    ONCOTARGET 7/7 :8055-8066,2016
  • Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
    CANCER RESEARCH AND TREATMENT 48/2 :499-507,2016
  • Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples
    EXPERIMENTAL AND MOLECULAR PATHOLOGY 100/2 :287-293,2016
  • Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
    ANNALS OF SURGERY 263/1 :96-102,2016
  • Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
    CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015
  • The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/12 :3938-3945,2015
  • The Impact of Coping Styles on Psychological Distress and Quality of Life in Korean Patients with Cancer
    Korean Journal of Psycho-Oncology(정신종양학회지) 1/1 :36-42,2015
  • Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas.
    GUT 64/11 :1721-1731,2015
  • Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial
    LANCET ONCOLOGY 16/7 :859-870,2015
  • LAMC2 enhances the metastatic potential of lung adenocarcinoma
    CELL DEATH AND DIFFERENTIATION 22/8 :1341-1352,2015
  • Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
    ONCOLOGY 88/3 :147-156,2015
  • Do Recent Advances in Diagnostic and Therapeutic Procedures Negate the Benefit of Postmastectomy Radiotherapy in N1 Patients With a Low Risk of Locoregional Recurrence?
    MEDICINE 94/33 :1-9,2015
  • Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
    AMERICAN JOURNAL OF CANCER RESEARCH 5/1 :72-86,2015
  • PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity
    INTERNATIONAL JOURNAL OF CANCER 136/10 :2273-2283,2015
  • Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children
    CANCER RESEARCH AND TREATMENT 47/1 :9-17,2015
  • Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
    ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015
  • PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
    ONCOLOGY 88/2 :76-85,2015
  • The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression.
    MOLECULAR CANCER THERAPEUTICS 13/12 :3074-3085,2014
  • Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
    LANCET ONCOLOGY 15/12 :1389-1396,2014
  • Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/4 :799-808,2014
  • High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients
    WORLD JOURNAL OF SURGICAL ONCOLOGY 12/- :232-238,2014
  • Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 10/3 :237-245,2014
  • Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial
    INVESTIGATIONAL NEW DRUGS 32/4 :753-761,2014
  • Quality of Life in the Trastuzumab for Gastric Cancer Trial
    ONCOLOGIST 19/7 :712-719,2014
  • Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
    JOURNAL OF CLINICAL ONCOLOGY 32/19 :2039-89,2014
  • A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer
    INVESTIGATIONAL NEW DRUGS 32/3 :561-568,2014
  • Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer
    PATHOLOGY 46/4 :316-324,2014
  • Influence of the BDNF Val66Met polymorphism on coping response to stress in patients with advanced gastric cancer
    JOURNAL OF PSYCHOSOMATIC RESEARCH 77/1 :76-80,2014
  • Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START)
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 140/2 :319-328,2014
  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
    JOURNAL OF CLINICAL ONCOLOGY 31/32 :4067-4075,2013
  • Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
    JOURNAL OF CLINICAL ONCOLOGY 31/31 :3935-3943,2013
  • S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial
    BMC CANCER 13/583 :1-7,2013
  • Prognostic Value of Mucinous Histology Depends on Microsatellite Instability Status in Patients with Stage III Colon Cancer Treated with Adjuvant FOLFOX Chemotherapy: A Retrospective Cohort Study
    ANNALS OF SURGICAL ONCOLOGY 20/11 :3407-3413,2013
  • Changing treatment patterns in elderly patients with resectable colon cancer
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 9/3 :265-272,2013
  • Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells
    ANTICANCER RESEARCH 33/6 :2499-2508,2013
  • Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors
    SUPPORTIVE CARE IN CANCER 21/6 :1751-1759,2013
  • Genome-Wide Identification and Validation of a Novel Methylation Biomarker, SDC2, for Blood-Based Detection of Colorectal Cancer
    JOURNAL OF MOLECULAR DIAGNOSTICS 15/4 :498-507,2013
  • Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43/10 :996-1003,2013
  • Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    LANCET ONCOLOGY 14/6 :490-499,2013
  • Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
    BMC CANCER 13/394 :1-7,2013
  • Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
    ANNALS OF SURGICAL ONCOLOGY 20/8 :2615-2624,2013
  • Estimating the Adjuvant Chemotherapy Effect in Elderly Stage II and III Colon Cancer Patients in an Observational Study
    JOURNAL OF SURGICAL ONCOLOGY 107/6 :613-618,2013
  • Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 31/5 :1202-1208,2013
  • Increased Alternative Lengthening of Telomere Phenotypes of Telomerase-negative Immortal Cells upon Trichostatin ? A Treatment
    ANTICANCER RESEARCH 33/3 :821-830,2013
  • Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    NATURE MEDICINE 19/3 :329-336,2013
  • Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer
    JOURNAL OF RADIATION RESEARCH 54/1 :52-60,2013
  • Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
    INVESTIGATIONAL NEW DRUGS 31/1 :1-13,2013
  • Quantitative Analysis of ERK Signaling Inhibition in Colon Cancer Cell Lines Using Phospho-Specific Flow Cytometry
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY 34/ :309-316,2012
  • Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells
    BMC GENOMICS 13/348 :-,2012
  • Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
    BMC CANCER 12/1 :471-471,2012
  • A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012
  • Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeuti
    JOURNAL OF CLINICAL ONCOLOGY 30/27 :3361-3367,2012
  • Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross-sectional study.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 8/3 :282-291,2012
  • Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
    PLOS ONE 7/9 :e45127-e45127,2012
  • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
    GUT 61/5 :673-684,2012
  • High levels of serum VEGF and TIMP-1 are correlated with colon cancer liver metastasis and intrahepatic recurrence after liver resection.
    Oncology letters 4/1 :123-130,2012
  • FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: A controlled and prospective study
    PSYCHONEUROENDOCRINOLOGY 37/ :1569-1576,2012
  • Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism
    SUPPORTIVE CARE IN CANCER 20/ :2177-2182,2012
  • AMPK alpha Modulation in Cancer Progression: Multilayer Integrative Analysis of the Whole Transcriptome in Asian Gastric Cancer
    CANCER RESEARCH 72/10 :2512-2521,2012
  • A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
    INVESTIGATIONAL NEW DRUGS 30/ :672-680,2012
  • A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer
    EUROPEAN JOURNAL OF CANCER 48/ :518-526,2012
  • A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer
    INVESTIGATIONAL NEW DRUGS 30/ :357-363,2012
  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
    LANCET 379/9813 :315-321,2012
  • Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer
    INTERNATIONAL JOURNAL OF ONCOLOGY 40/3 :889-898,2012
  • Methylation Status of Lamin A/C in Gastric Cancer Cell Lines
    HEPATO-GASTROENTEROLOGY 59/116 :1313-1318,2012
  • DNA Methylation Predicts Recurrence From Resected Stage III Proximal Colon Cancer
    CANCER 117/9 :1847-1854,2011
  • MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
    HEPATO-GASTROENTEROLOGY 58/112 :2015-2019,2011
  • A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures
    PLOS GENETICS 7/12 :-,2011
  • Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 41/ :1344-1350,2011
  • Phase II study of sunitinib as second-line treatment for advanced gastric cancer
    INVESTIGATIONAL NEW DRUGS 29/ :1449-1458,2011
  • Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 68/0 :991-999,2011
  • Treatment of recurrent hepatocellular carcinoma after liver transplantation
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 7/3 :258-269,2011
  • Inflammatory and Tumor Stimulating Responses after Laparoscopic Sigmoidectomy
    YONSEI MEDICAL JOURNAL 52/4 :635-642,2011
  • CD44-SLC1A2 Gene Fusions in Gastric Cancer
    SCIENCE TRANSLATIONAL MEDICINE 3/77 :1-11,2011
  • Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    BREAST CANCER 18/3 :203-212,2011
  • Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
    ONCOLOGY 80/5-6 :395-405,2011
  • A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis
    ONCOLOGY 80/1-2 :142-150,2011
  • Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer
    ANTI-CANCER DRUGS 22/8 :801-810,2011
  • A Randomized Phase 2 Study of Docetaxel and S-1 Versus Docetaxel and Cisplatin in Advanced Gastric Cancer With an Evaluation of SPARC Expression for Personalized Therapy
    CANCER 117/10 :2050-2057,2011
  • Prevalence and associated factors of psychological distress among Korean cancer patients
    GENERAL HOSPITAL PSYCHIATRY 33/3 :246-252,2011
  • Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 137/7 :1123-1130,2011
  • Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis
    ONCOLOGY REPORTS 25/3 :717-727,2011
  • Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
    BREAST CANCER RESEARCH AND TREATMENT 125/1 :55-63,2011
  • Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma
    International Journal Of Hyperthermia 26/4 :305-315,2010
  • Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
    Cancer Research and Treatment 42/4 :217-224,2010
  • The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
    Annals of Surgical Oncology 17/12 :3259-3268,2010
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Lancet 376/9742 :687-697,2010
  • Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/3 :425-431,2010
  • Is pyridoxine helpful in preventing palmar-plantar erythrodysesthesia associated with capecitabine?
    Asia-Pacific Journal Of Clinical Oncology 6/3 :141-143,2010
  • Identification of Novel Gastric Cancer-Associated CNVs by Integrated Analysis of Microarray
    Journal Of Surgical Oncology 102/5 :454-461,2010
  • Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
    CANCER SCIENCE 101/10 :2200-2206,2010
  • A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer
    Investigational New Drugs 28/5 :650-658,2010
  • Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 66/4 :797-805,2010
  • Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
    Breast Cancer Research and Treatment 122/2 :409-418,2010
  • A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis
    Scandinavian Journal Of Gastroenterology 45/2 :217-225,2010
  • A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma
    Anti-Cancer Drugs 21/8 :777-784,2010
  • Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer
    Radiotherapy And Oncology 95/3 :303-307,2010
  • The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/ :517-526,2010
  • Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/12 :1901-1913,2010
  • A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer
    American Journal of Clinical Oncology-Cancer Clinical Trials 33/1 :56-60,2010
  • Association of the ABCB1 3435C > T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy
    Oncology Reports 23/ :271-278,2010
  • Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m(2) bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 40/1 :29-35,2010
  • Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients
    Cancer Letters 288/1 :124-132,2010
  • Benefits of Recurrent Colonic Stent Insertion in a Patient with Advanced Gastric Cancer with Carcinomatosis Causing Colonic Obstruction
    Yonsei Medical Journal 50/2 :296-299,2009
  • Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer
    European Journal Of Cancer 45/17 :2940-2946,2009
  • Changes of Telomerase Activity by Alternative Splicing of Full-Length and beta Variants of hTERT in Breast Cancer Patients
    Oncology Research 18/5-6 :213-220,2009
  • Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
    Cancer Research And Treatment 41/4 :196-204,2009
  • A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status
    Oncology 77/6 :349-357,2009
  • Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer
    Journal Of Surgical Oncology 100/6 :459-465,2009
  • Standardized genetic alteration score and predicted score for predicting recurrence status of gastric cancer
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 135/11 :1501-1512,2009
  • Prognosis of pN3 stage gastric cancer
    Cancer Research And Treatment 41/2 :73-79,2009
  • Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in korea
    Cancer Research And Treatment 41/2 :67-72,2009
  • oncogenic pathway combinations predict clinical prognosis in gastric cancer
    Plos Genetics 5/ :e1000676-,2009
  • Genetic and Epigenetic Marker-Based DNA Test of Stool Is a Promising Approach for Colorectal Cancer Screening
    Yonsei Medical Journal 50/3 :331-334,2009
  • A weighted sample size for microarray datasets that considers the variability of variance and multiplicity
    Journal Of Bioscience And Bioengineering 108/3 :252-258,2009
  • Identification of significant regional genetic variations using continuous CNV values in aCGH data
    Genomics 94/3 :317-323,2009
  • Prediction of recurrence of early gastric cancer after curative resection
    Annals Of Surgical Oncology 16/7 :1896-1902,2009
  • Subtelomeric DNA methylation and telomere length in human cancer cells
    Cancer Letters 281/1 :82-91,2009
  • Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer
    International Journal Of Oncology 34/3 :787-796,2009
  • Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery
    International Journal Of Oncology 34/ :837-846,2009
  • Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma
    Journal Of Gastroenterology And Hepatology 24/3 :475-479,2009
  • The Effect of Spleen-Preserving Lymphadenectomy on Surgical Outcomes of Locally Advanced Proximal Gastric Cancer
    Journal Of Surgical Oncology 99/ :275-280,2009
  • G-T haplotype (2677G > T/A and 3435C > T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern
    Cancer Letters 277/2 :155-163,2009
  • A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/ :1083-1090,2009
  • Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Breast Cancer Research And Treatment 114/3 :589-595,2009
  • Prediction of S-1-induced anemia
    GASTRIC CANCER 12/ :23-30,2009
  • Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 63/5 :919-927,2009
  • Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
    Annals Of Oncology 20/2 :272-277,2009
  • Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast
    Human Pathology 40/1 :98-107,2009
  • In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer
    Genomics 93/ :52-61,2009
  • Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer
    Cancer Letters 270/2 :269-276,2008
  • Disease Prediction Using Ranks of Gene Expressions
    Genomics & Informatics 6/3 :136-141,2008
  • Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity
    Psycho-Oncology 17/ :592-597,2008
  • Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
    Annals Of Oncology 19/6 :1135-1140,2008
  • Cyclooxygenase-2 Expression in Pretreatment Biopsy as a Predictor of Tumor Responses After Preoperative Chemoradiation in Rectal Cancer
    Archives Of Surgery 143/ :1091-1097,2008
  • Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma
    Molecular Cancer Research 6/10 :1554-1566,2008
  • S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer
    The Korean Journal Of Internal Medicine 23/1 :37-41,2008
  • Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene
    Cancer Research 68/ :4277-4286,2008
  • Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions
    Bmc Bioinformatics 9/ :-,2008
  • Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases
    Annals Of Oncology 19/ :1146-1153,2008
  • Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A : U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up
    Annals Of Oncology 19/ :520-526,2008
  • A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :315-321,2008
  • Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
    Cancer Chemotherapy And Pharmacology 62/ :263-270,2008
  • Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: Long-term results in 31 patients
    Bmc Cancer 8/ :-,2008
  • Novel biomarker candidates for gastric cancer
    Oncology Reports 19/ :675-680,2008
  • The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer
    Cancer Chemotherapy And Pharmacology 61/ :75-81,2008
  • Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer
    Cancer Chemotherapy And Pharmacology 61/ :157-165,2008
  • Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer
    Radiotherapy And Oncology 87/ :361-366,2008
  • Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
    Breast Cancer Research And Treatment 108/ :241-250,2008
  • Variation of the 3 ` telomeric overhang lengths in human cells
    Cancer Letters 264/ :107-118,2008
  • 화학요법 치료 중인 암 환자에서의 Vibrio fluvialis 균혈증 2례
    대한임상미생물학회지 10/2 :164-167,2007
  • Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
    JOURNAL OF CLINICAL ONCOLOGY 25/33 :5210-5217,2007
  • A Locally Advanced Breast Cancer with Difficult Differential Diagnosis of Carcinosarcoma and Atypical Medullary Carcinoma, which had Poor Response to Adriamycin- and ...
    BREAST CANCER RESEARCH AND TREATMENT 39/3 :134-137,2007
  • Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: A 15-year follow-up study at a single korean institute
    ANNALS OF SURGICAL ONCOLOGY 14/ :2730-2737,2007
  • Novel and simple transformation algorithm for combining microarray data sets
    BMC BIOINFORMATICS 8/ :310-316,2007
  • Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization
    BMC GENOMICS 8/ :749-754,2007
  • An Attempt for Combining Microarray Data Sets by Adjusting Gene Expressions
    Cancer Research and Treatment 39/2 :74-81,2007
  • Molecular basis of the differences between normal and tumor tissues of gastric cancer
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE 1772/ :1033-1040,2007
  • A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :313-320,2007
  • Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 356/1 :233-238,2007
  • Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents
    ONCOLOGY REPORTS 18/ :593-599,2007
  • An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients
    ONCOLOGIST 12/ :622-630,2007
  • Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute
    JOURNAL OF SURGICAL ONCOLOGY 95/ :461-468,2007
  • Whole genome analysis for liver metastasis gene signatures in colorectal cancer
    INTERNATIONAL JOURNAL OF CANCER 121/ :2005-2012,2007
  • Gastrointestinal stromal tumor of the rectum: An analysis of seven cases
    SURGERY TODAY 37/6 :455-459,2007
  • Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy
    ACTA ONCOLOGICA 46/4 :547-549,2007
  • Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
    ONCOLOGIST 12/5 :543-554,2007
  • A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
    BRITISH JOURNAL OF CANCER 97/ :458-463,2007
  • A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 67/1 :204-210,2007
  • Entropy-based analysis of the non-linear relationship between gene expression profiles of amplified and non-amplified RNA
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20/6 :905-912,2007
  • Bilateral breast cancer: Differential diagnosis using histological and biological parameters
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 37/ :487-492,2007
  • Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 104/ :31-37,2007
  • Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer
    GENOMICS 89/ :451-459,2007
  • Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)
    CANCER CHEMOTHERAPY AND PHARMACOLOGY 59/ :295-300,2007
  • Integrated in silico and biological validation of the blocking effect of C(o)t-1 DNA on microarray-CGH
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 19/ :901-908,2007
  • A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
    BRITISH JOURNAL OF CANCER 95/ :1637-1641,2006
  • A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer
    ONCOLOGY 70/ :63-70,2006
  • Intermediate dose 5-fluorouracil-induced encephalopathy
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 36/ :55-59,2006
  • 유방암의 전신적 재발로 오인된 톡소플라스마증 1예
    대한내과학회지(korean Journal of medcine) 71/1 :108-113,2006
  • Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines
    PHARMACOGENETICS AND GENOMICS 16/ :429-438,2006
  • Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer.
    ONCOLOGY REPORTS 15/ :749-755,2006
  • Activation of hypoxia-inducible factor-1α is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression
    CLINICAL CANCER RESEARCH 12/21 :6351-6358,2006
  • Significant Gene Selection Using Integrated Microarray Data Set with Batch Effect
    GENOMICS & INFORMATICS 4/3 :110-117,2006
  • Long-term Survival after Surgical Resection for Liver Metastasis from Gastric Cancer: Two Case Reports
    CANCER RESEARCH AND TREATMENT 38/3 :184-188,2006
  • Severe hypothyroidism induced by thyroid metastasis of colon adenocarcinoma: A case report and review of the literature
    ENDOCRINE JOURNAL 53/3 :339-343,2006
  • Systematic analysis of cDNA microarray-based CGH.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 17/ :261-267,2006
  • Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
    ANNALS OF ONCOLOGY 16/ :1778-1785,2005
  • A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma
    YONSEI MEDICAL JOURNAL 46/6 :799-805,2005
  • Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction
    FEBS LETTERS 579/ :127-132,2005
  • Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 16/5 :857-863,2005
  • Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells
    INTERNATIONAL JOURNAL OF CANCER 114/ :484-489,2005
  • Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients
    CLINICAL CANCER RESEARCH 11/ :612-620,2005
  • Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray
    CLINICAL CANCER RESEARCH 11/ :79-86,2005
  • Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss
    BREAST CANCER RESEARCH AND TREATMENT 93/ :227-236,2005
  • 직장암에서 전 직장간막 절제술 후 측방절제연이 예후에 미치는 영향
    대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 21/5 :307-313,2005
  • 진행된 직장암에서 수술 전 화학 방사선 요법 후 전직장간막절제술의 임상적 고찰: 병리학적 T 병기와 N 병기하강에 따른 임상 결과 분석
    대한외과학회지 68/3 :218-223,2005
  • Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer
    BREAST CANCER RESEARCH AND TREATMENT 90/3 :215-221,2005
  • 직장에 발생한 위장관 간질종양 7예
    대한외과학회지 68/2 :117-122,2005
  • The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 13/1 :17-24,2004
  • Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines
    CANCER LETTERS 214/ :215-224,2004
  • Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas
    LEUKEMIA & LYMPHOMA 45/9 :1857-1864,2004
  • Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival
    CLINICAL CANCER RESEARCH 10/4 :1366-1374,2004
  • Statistical methods of determining a cut off value between normal and disease groups
    Bulletin of Informatics and Cybernetics 36/ :63-72,2004
  • MN/CA9 촉진자를 가진 Replication-competent 아데노바이러스를 이용한 신세포암에 대한 종양 특이적 유전자요법
    Korean Journal of Urology 45/5 :456-462,2004
  • Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model
    WORLD JOURNAL OF GASTROENTEROLOGY 10/8 :1191-1197,2004
  • A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
    ANNALS OF ONCOLOGY 15/ :1344-1347,2004
  • 국소 진행된 직장암의 수술 전 화학방사선 요법 치료 후 종양반응 분석: 종양체적 변화와 병리조직학적 병기하강과의 상관관계 분석
    대한대장항문학회지(Journal Of The Korean Society Of Coloproctology) 20/5 :296-302,2004
  • A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma
    YONSEI MEDICAL JOURNAL 44/3 :539-543,2003
  • Infusional Fluorouracil, Etoposide, and Cisplatin(FEP) in Advanced and Relapsed Gastric Cancer
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 26/2 :203-209,2003
  • Region of allelic imbalance in the distal portion of chromosome 12q in gastric cancer
    MOLECULAR PHARMACOLOGY 0/0 :0-0,2003
  • Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray
    Int J Oncology 22/0 :741-750,2003
  • cDNA microarray experiment: disign issues in early stage and the need of normalization
    CANCER RESEARCH AND TREATMENT 35/6 :533-540,2003
  • Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
    BRITISH JOURNAL OF SURGERY 89/4 :460-466,2002
  • Changes of telomerase activity and proliferation by inhibition of reverse transcriptase activity in human cancer cell.
    Cencer Research and Treatment 34/0 :223-233,2002
  • A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
    CANCER RESEARCH AND TREATMENT 34/4 :274-279,2002
  • Suppression of peritoneal metastasis by expression of murine endostatin cDNA
    CANCER RESEARCH AND TREATMENT 34/4 :302-307,2002
  • Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.
    Int J Mol Oncol 10/3 :251-256,2002
  • Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    Cancer Research and Treatment 33/6 :520-526,2001
  • 전이성 유방암의 치료
    Current diagnosis and management of cancer 1/3 :171-180,2001
  • 암치료에 있어 혈관신생 연구
    대한내분비학회지(Joornal of the Korean Society of Endocrinol) 16/3 :313-327,2001
  • A phase II study of genexol in metastatic breast cancer
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY 33/6 :451-457,2001
  • The significance of granzyme B expression in patients with angiocentric lymphoma of the head and neck
    CANCER 91/0 :2343-2352,2001
  • Leptomeningeal Carcinomatosis in Solid Tumors ; Clinical Manifestation and Treatment
    대한암학회지 33/1 :34-40,2001
  • Intravenous 5-fluorouracil versus oral doxifluridine as pre-operative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY 31/0 :25-29,2001
  • Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
    CANCER 91/11 :2016-2025,2001
  • 5-days 5-fluorouracil and low dose leucovorin for adjuvant chemotherapy in colon cancer
    CANCER LETTERS 167/0 :215-224,2001
  • Efficacy of Pre - and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities
    대한암학회지 33/6 :520-526,2001
  • Early post-operative intraperitoneal chemotherapy with mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer
    ONCOLOGY 60/1 :24-30,2001
  • Tissue urokinase-type plasminogen activator receptor levels in breast cancer
    International J Mol Medicine 6/0 :301-305,2000
  • 국소진행성 직장암에서 수술전 방사선 및 항암화학 동시요법의 효과
    대한방사선종양학회지(Journal Of The Korean Society For Therapeutic Radiology And Oncology) 18/4 :293-299,2000
  • 정상임신과 자궁외 임신 사이의 융모막 융모 telomerase 활성도의 비교
    대한산부회지 43/8 :1431-1436,2000
  • 유방암의 출력 도플러 초음파 소견: 병리학적 미세혈관 정도 및 림프절 전이와 비교
    대한초음파의학회지(Journal Of The Korean Society Of Medical Ultrasound) 19/ 4 :319-323,2000
  • 위암에서 ex vivo Model 을 이용한 MMP - 9 에 대한 Gabexate Mesylate IC50의 응용 : 예후인자 및 치료대상 선정기준
    대한암학회지 32/1 :7-18,2000
  • 유방암 조직에서 uPAR 발현의 임상적 의의
    대한암학회지 32/0 :53-59,2000
  • Correlation of tissue and blood plasminogen activation system in breast cancer
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 150/0 :137-145,2000

정현철

진료철학
자신의 몫을 아는 일관성 있는 의사

의학은 뛰어난 창조성 보다는 평생을 뚜벅 뚜벅 걸을 수 있는 꾸준함이 필요한 학문입니다. 평범하기 때문에 멀리 가지는 못하더라도 뚜벅뚜벅 걸으면서 다른 사람들 보다 조금 더 많이 갈수 있는 것은 자신의 일에 대한 용기와 일관성에 의해서입니다. 뛰어난 재능이나 자원, 풍부한 경험과 좋은 환경에 있더라도 일관성이 부족하면 아무것도 이룰 수가 없습니다. 중심을 잃지 않는 일관성은 환자와 보호자에게서 믿음으로 나타납니다.

인간은 자신의 입장을 선택함으로써 운명을 변화시킬 수 있다고 합니다. 유능한 의료진이 되는 것도 자신의 선택입니다. 봉사와 희생으로 얻은 자기 몫의 권위만이 다른 사람들이 진정 마음속으로부터 따를 수 있습니다. 자신을 따르는 사람들로부터 인기를 얻으려는 유혹을 물리치고 그 사람들을 올바른 방향으로 유도할 수 있는 의사가 되어야 합니다.

인간이 아름다운 이유는 슬퍼도, 또는 상처 받아도 서로를 위로하며 어떻게 사랑하며 살아가는가를 추구할 줄 알기 때문이라 합니다. 우리가 일생 살아가면서 진료실에서 만나는 분들은 홀로 견딜 수 없고 따뜻한 위로와 사랑이 필요한 사람들입니다. 서로가 위로함으로 위로를 받고 사랑함으로 사랑을 받기 원하는 삶들입니다. 이러한 삶들 속에서 의사로서 자기 몫을 스스로 찾아내고 알아야 합니다. 이 자기 몫은 혼자서 움켜쥐라는 것이 아니고 잘 쓰라고 잠시 주어지는 특별한 선물입니다. 이 세상에는 자신에게 주어진 선물을 잘 나누는 의사가 필요합니다

콘텐츠 처음으로 이동

네크워크 링크안내/사이트 정보